The ShcA adaptor protein transduces oncogenic signals downstream of receptor tyrosine kinases. We show here that breast tumors engage the ShcA pathway to increase their metabolism. ShcA signaling enhanced glucose catabolism through glycolysis and oxidative phosphorylation, rendering breast cancer cells critically dependent on glucose.
INTRODUCTION
Metabolic reprogramming represents an emerging hallmark in order for cancers to meet their energetic and biosynthetic demands (1) . To achieve this, cancer cells coordinate ATP-producing (glycolysis and oxidative phosphorylation) and ATPconsuming (protein, nucleotide and lipid synthesis) processes. This reprogramming is often coupled to distinct nutrient dependencies, exposing targetable metabolic vulnerabilities that are being exploited in cancer clinical trials. For example, Warburglike cancers undergo glycolysis, even when oxygen levels are plentiful. Pyruvate is preferentially converted to lactate instead of being fully metabolized through the citric acid cycle (CAC) and oxidative phosphorylation for further ATP generation (2) . This adaptive response permits increased biosynthesis to support cell division. Warburg-like tumors compensate for inefficient ATP production by increasing glucose uptake, which forms the basis for 18 Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) imaging as a diagnostic tool to detect malignant lesions (3) . Indeed, a nonhydrolyzable glucose analogue (2-deoxy-D-glucose) is being tested as a therapeutic in Warburg-like cancers (4) , including in combination with tyrosine kinase inhibitors (5, 6) . Some aggressive cancers also use glutamine to increase ATP production and synthesis of CAC intermediates through reductive carboxylation to support lipid synthesis (7, 8) . This requires the activity of two glutaminases (GLS1, GLS2), which convert glutamine to glutamate. Glutamate can be used as an intermediate for amino acid synthesis, redox balance or it can enter the CAC through its conversion into -6 | P a g e proliferation. Given previous observations that RTKs engage ShcA to coordinately increase breast cancer proliferation and angiogenesis (23,25), we reasoned that this pathway would also play a central role in metabolic rewiring of breast cancer cells.
Indeed, we identified a novel role for ShcA in coordinating metabolic reprogramming of breast cancers. ShcA upregulates the expression and activity of the key metabolic regulator, PGC-1, in breast cancer cells, leading to an elevated global bioenergetic capacity and increased glucose dependency. Attenuation of ShcA signaling reduces the metabolic rate of breast cancer cells and makes them more dependent on glutamine.
Moreover, the anti-neoplastic effects of biguanides are potentiated when ShcA signaling is impeded in mammary tumors. Thus, the ShcA/PGC-1α axis is a novel determinant of metabolic reprogramming and sensitivity to metabolic disrupters, such as biguanides.
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Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472. MATERIALS AND METHODS Cell Lines. NMuMG-NT2197 are immortalized NMuMG mouse mammary epithelial cells that were obtained from the ATCC and subsequently transformed with an oncogenic variant of rat ErbB2 (Neu) and have been described previously (27) . The stable cell lines overexpressing wild-type ShcA (ShcA WT ) or a ShcA-Y239/240/313F mutant (Shc3F) were also described (25). ErbB2/Shc3F cells were further transfected with pQCXIB/PGC1α or pQCXIB empty vector to generate (PGC1α O/E) and Shc3F (EV) respectively. To generate the PGC-1α/pQCXIB vector, PGC-1α was sub-cloned from pcDNA-f:PGC1 (Addgene Plasmid#1026). The MT/ShcA +/+ and MT/Shc 3F/+ cell lines employed in this study were generated from MMTV/MT transgenic mouse mammary days. All cell lines were not cultured for longer than one month prior to replenishing with a fresh stock of cells. Cell authentication was not performed as the NMuMG cell line used was purchased from the ATCC and the MT/ShcA cell lines were established by our group from MMTV/MT transgenic tumors. All cell lines were routinely tested for mycoplasma using the Mycoprobe mycoplasma detection kit (R&D; Cat# CUL00IB).
Mice. MMTV/MT have been described (28). Mice expressing mutant ShcA protein containing tyrosine-to-phenylalanine point mutations at residues 239/240/313 (Shc3F) under the control of the endogenous ShcA promoter have been described (29) . SCIDon July 20, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472. Beige mice were purchased from Charles River Laboratories. For mammary fat pad injection, 5 x 10 5 cells were injected into the fourth mammary fat pad of female mice (6 -10 weeks of age). Tumor growth was monitored every two days via caliper measurements and tumor volumes were calculated as previously described (25) . Phenformin (Cat#P296900, Toronto Research Chemicals) treatment was carried out via daily intraperitoneal injection (50 mg/kg) for the orthotopic studies. For the transgenic studies, MMTV/ShcA +/+ and MMTV/ShcA 3F/+ transgenic mice were monitored for tumor onset by bi-weekly physical palpation and following detection of one tumor-bearing gland, were either given water alone or received 200 mg/kg phenformin in their drinking water with 50mg/ml of sucrose for 4-5 weeks, where fresh phenformin was administered 2~3 times per week. All animal studies were approved by the Animal Resources Council Briefly, cells were seeded at 30 000 cells per well in 250µL of culture media and, after incubating overnight in a 37°C incubator, cells were washed twice with XF base media (Agilent), supplemented with 25mM glucose, 4mM glutamine, and 1mM sodium pyruvate. A final volume of 525µL supplemented XF media was added, and the plate was set to incubate for 1 hour in a CO2-free incubator at 37°C. OCR and ECAR were obtained by repeated cycles of mix (3min), pause (3min), and measurement (3min).
Measurements were normalized on protein content at the end of the experiment. % μL of N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA, > 97%; Sigma-Aldrich), transferred in sealed glass vials, and then incubated for 1h at 70°C. GC/MS analysis was performed by injection of 1 μL of derivatized sample into GC/MS instrument (5975C; Agilent, CA, USA). Data acquisition was done in both Scan and SIM (Selected Ion Monitoring) modes as described in (31, 32) . The isotopic distribution of integrated ions was determined using Agilent MassHunter software. The steady state level was determined for each metabolite and normalized by cell number and internal standard (myristic acid-D 27 ) intensity. Isotopic distributions were corrected for naturally occurring isotopes to isolate contributions from our tracers using an in-house algorithm according to (32, 33) . Enrichments for specific isotopomers (e.g. m+3), termed proportional ion amount, were presented as proportions of the total isotopic distribution for each metabolite. Total abundance of specific isotopomers, termed relative ion amount, was assessed for each metabolite by multiplying proportional ion amounts by the normalized steady state levels.
NMR Sample preparation.
Tumors were flash frozen directly after dissection, ground to a fine powder using a mortar and pestle on liquid nitrogen, weighed (15 to 59 mg) and transferred to 2ml Eppendorf micro-centrifuge tubes. Six pre-washed and chilled 1.4mm ceramic beads were added to each sample along with 1.5 ml of cold 80% methanol in water (both LC/MS grade solvents). The samples were subjected to two minutes of bead beating (TissueLyser II -Qiagen, GmbH, Germany). Precipitated proteins and tissue debris were removed by centrifugation at 15 krpm and 1 o C for 10 min. Supernatants were transferred to chilled tubes and dried by vacuum centrifugation (Labconco, Kansas City MO, USA) with sample temperature maintained at -4 o C. Samples were subsequently re- Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472.CAN-17-3696 unpaired student's t test Holm-Sidak method ( Figure 6D -F); One-way ANOVA with a Tukey's multiple comparisons test ( Figure 3C -E, 5F-I, S1B-C, S2A); Two-way ANOVA with a Tukey's multiple comparisons test ( Figure 4B , 4D, 5B-E, 6C, S2B-D, S5B-C, S7).
Statistical significance is shown as follows: *P,0.05; **P<0.01; ***P,0.001, ****P<0.0001. 
RESULTS
The ShcA adaptor increases the metabolic rate and glucose dependency of breast tumors. Since the ShcA adaptor is a critical signaling hub downstream of RTKs for mammary tumor initiation, growth and angiogenesis (23,34), we sought to establish whether its also plays a role in metabolic reprogramming. To test this, we modulated ShcA signaling in ErbB2-transformed NMuMG breast cancer cells by ectopically expressing FLAG-tagged ShcA-proficient (ShcA WT ) or -deficient (Y239/240/313F; Shc3F) alleles. The Shc3F allele serves as a dominant negative mutant ( Figure 1A ) (25).
We show comparable ShcA WT -FLAG and Shc3F-FLAG expression levels in both cell lines ( Figure S1A ). Moreover, expression of the Shc3F mutant severely impairs mammary tumor growth in an orthotopic mouse model relative to ShcA WT -controls ( Figure 1B ). We previously showed that impaired ShcA signaling reduces the proliferative and angiogenic capacities of these tumors in vivo (23,24). We now show that Shc3F-expressing cells are less metabolically active, as evidenced by 20% and 10% decreased rates of glycolysis (extracellular acidification rate, ECAR) and mitochondrial respiration (oxygen consumption rate, OCR) compared to ShcA WT cells ( Figure 1C ).
Nonetheless, AMPK Thr-172 phosphorylation was reduced in Shc3F-expressing cells ( Figure 1D ) and mammary tumors ( Figure 1E ) compared to their ShcA WT counterparts. This is coincident with reduced AMP levels in Shc3F mammary tumors ( Figure 1F ).
Taken together, these data suggest that RTKs engage the ShcA pathway to promote metabolism.
With the knowledge that many breast tumors acquire a Warburg-like metabolism, we next assessed whether modulating the ShcA pathway in breast cancer cells altered on July 20, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. their glucose dependency. While inhibition of ShcA signaling does not impact breast cancer cell growth in glucose replete conditions (25 mM), Shc3F cells acquire a growth advantage when glucose levels are reduced (5 mM) or absent (0 mM) ( Figure 1G ). In contrast, ectopic expression of wild-type ShcA sensitizes ErbB2-NMuMG cells to glucose deprivation to levels that are comparable to parental cells ( Figure S1B ). To further support our findings, we tested the glucose dependency of MT-transformed breast cancer cells that originated from transgenic mice (MT/ShcA +/+ vs. MT/ShcA 3F/+ ) (25) expressing the Shc3F allele under the control of the endogenous ShcA promoter. We show that impaired ShcA signaling increases cell viability upon glucose withdrawal in cells expressing physiological levels of the Shc3F mutant ( Figure S1C ). These data suggest that reduced ShcA signaling endows breast cancer cells with the potential to grow under glucose-deprived conditions. We next assessed whether reduced ShcA signaling is associated with impaired glucose metabolism in mammary tumors. We show that inhibition of ShcA signaling (Shc3F) significantly increases glucose levels in mammary tumors relative to ShcA WT controls ( Figure 1H ). Despite this fact, Shc3F tumors possess reduced lactate levels and a significant reduction in the lactate/glucose ratio compared to ShcA WT tumors ( Figure   1H ), coincident with their reduced growth potential ( Figure 1B ). mitochondrial respiration (oxygen consumption rate, OCR) compared to ShcA WT cells ( Figure 1C ).
Moreover, steady state levels of glycolytic and citric acid cycle (CAC) metabolites, including pyruvate, -ketoglutarate, fumarate and malate were also reduced in Shc3F cells compared to ShcA WT cells ( Figure S2A ). This suggest that attenuated ShcA on July 20, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. signaling decreases the ability of mammary tumors to metabolize glucose, resulting in a reduced bioenergetic capacity.
To better understand the impact of glucose deprivation on metabolic adaptations in ShcA WT and Shc3F cells, we measured glycolytic and CAC metabolite levels in each cell line cultured in the presence or absence of glucose. Compared to ShcA WT cells, steady state levels of pyruvate along with several CAC metabolites (citrate, ketoglutarate, fumarate, malate) are less depleted in Shc3F breast cancer cells upon glucose withdrawal (Figure 2A ). This suggests that decreased ShcA signaling reduces the metabolic activity of breast cancers, allowing them to withstand glucose deprivation.
Impaired ShcA signaling increases the glutamine dependency of breast cancer cells.
Given its importance as an alternative energy source in a subset of cancers (8), we investigated whether impaired ShcA signaling instead increases the glutamine dependency of breast cancer cells. We first measured how ShcA WT and Shc3F cancer cells modulate glutamine and glutamate levels following glucose withdrawal. Increased glutamate production may indicate enhanced glutamine metabolism (8) . Although glutamine levels are unaffected, Shc3F cells display a robust increase in glutamate levels following glucose deprivation, suggesting that they efficiently metabolize glutamine in the absence of glucose ( Figure 2B ). We next compared the relative viability of ShcA WT and Shc3F cells in response to glucose versus glutamine deprivation. Whereas Shc3F cells better withstand glucose withdrawal, they are more sensitive to glutamine deprivation relative to ShcA WT controls ( Figure 2C ). These data suggest that inhibition of ShcA signaling increases the glutamine dependency of breast cancer cells.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472. Considering these observations, we measured glutamine and glutamate levels in ShcA WT and Shc3F mammary tumors. Compared to ShcA WT controls, tumors with reduced ShcA signaling display increased glutamine levels, coincident with decreased glutamate levels ( Figure 2D ). The increased lactate/glucose ( Figure 1H ) and glutamate/glutamine ( Figure 2D ) ratios in ShcA WT -expressing tumors suggests that they increase their bioenergetic capacity through enhanced glucose and glutamine metabolism yet are exquisitely reliant on glucose availability. Even though Shc3F cells reduce their bioenergetic capacity and are less dependent on glucose, they instead reprogram their metabolism to rely on glutamine.
Impaired ShcA signaling sensitizes breast cancers to biguanides.
Biguanides (metformin and phenformin) block complex I of the electron transport chain (12) (13) (14) and render cells dependent on glycolysis (10, 12, 15) . We next asked whether inhibition of ShcA signaling in breast cancer cells exposes a metabolic vulnerability to biguanides. In agreement with their reduced glycolytic capacity and enhanced dependence on oxidative phosphorylation, Shc3F cells are more sensitive to phenformin compared to ShcA WT cells in vitro ( Figure 3A ). We next injected ShcA WT -and Shc3Fexpressing cells into the mammary fat pad of immunodeficient mice to determine whether ShcA signaling impacted the sensitivity of mammary tumors to phenformin in vivo. ShcA WT tumor growth is minimally affected by phenformin treatment ( Figure 3B ), even though we observe increased pAMPK immunohistochemical staining ( Figure 3C ).
Phenformin did not impact the proliferative capacity of ShcA WT tumors ( Figure 3D ) but increased their apoptotic response ( Figure 3E ). This is consistent with the inability of on July 20, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472. ShcA WT cells to reduce their metabolic rate under nutrient stress ( Figure 1G , 2A). The relative insensitivity of ShcA WT tumors to phenformin in vivo ( Figure 3B ) can be explained by their enhanced bioenergetic capacity and metabolic flexibility to increase the rate of glycolysis.
In contrast, the growth potential of Shc3F tumors was significantly blunted (40% reduction in tumor volume) following phenformin treatment in vivo ( Figure 3B Figure 4B ). Accounting for the larger steady state pool of each metabolite in ShcA WT cells ( Figure 4C , S2B), these data support the fact that ShcA increases the glycolytic capacity of breast cancer cells ( Figure 1B ), resulting in a higher quantitative glycolytic flux. Despite this fact, the lactate/pyruvate ratio is similar between ShcA WT and Shc3F cells ( Figure S2C ). These data suggest that ShcA signaling globally on July 20, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472.CAN-17-3696 increases glucose metabolism both through glycolysis and conversion to lactate or its metabolism through the CAC. Indeed, we show that the ability of (m+3) pyruvate to enter the CAC, either to generate ATP (green bars) or for macromolecular synthesis (blue bars) is comparable between ShcA WT and Shc3F-expressing cells ( Figure 4D, S3 ). Again, considering the larger pool of CAC metabolites in ShcA WT -expressing cells ( Figure 4C , S2A), these data reinforce the fact that glucose flow through the CAC is globally increased by elevated ShcA signaling.
As expected, phenformin significantly increased glycolysis in both ShcA WT and Shc3F cells ( Figure 4B , S3). Coupled with the drastic increase in the steady state pools of glycolytic metabolites ( Figure 4C , S2A), these data are consistent with studies reporting a strict reliance on aerobic glycolysis in the presence of biguanides (10, 12, 15) . While phenformin increased the lactate/pyruvate ratio in ShcA WT and Shc3F-expressing cells, the induction was stronger in ShcA WT cells ( Figure S2C ). These data indicate that ShcA signaling increases the glycolytic capacity of breast cancer cells, rendering them better able to cope with biguanide treatment ( Figure 3A ). Moreover, phenformin drastically reduced the forward flow of glucose-derived metabolites into the CAC in both ShcA WT and Shc3F-expressing cells ( Figure 4D ; Figure S3 ). In contrast, phenformin promoted anaplerosis (reverse flow) to replenish CAC intermediates. Combined these data suggest that phenformin blocks mitochondrial glucose metabolism independently of the ShcA pathway.
Given that inhibition of ShcA signaling in breast cancer cells increases their glutamine reliance ( Figure 2C ), we also examined the fate of [U- 13 Figure S4 ).
Reductive carboxylation of glutamine occurs mainly in cancer cells with defective mitochondria or under reductive conditions, like hypoxia and exposure to biguanides (35-37). There was no significant difference in the metabolism of glutamine through the canonical CAC between ShcA WT and Shc3F-expressing cells ( Figures S4, S5A 
PGC-1 is essential for ErbB2-driven breast tumor initiation and resistance to
biguanides. The PGC-1 transcriptional co-activator is a master regulator of energy metabolism (38) and is induced upon nutrient stress (39). Strikingly, we observed that ShcA signaling increases PGC-1 expression. Indeed, PGC-1 levels are 3.9-fold higher in ShcA WT cells compared to Shc3F cells ( Figure 5A ). To interrogate whether ShcA Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472.CAN-17-3696 signaling increases the PGC-1 dependency of breast cancer cells, we employed shRNA approaches to stably reduce Ppargc1a mRNA levels in cells that differ in their ability to engage the ShcA pathway. This includes ErbB2/ShcA WT and ErbB2/Shc3F cells in addition to two independent explants from MT/ShcA +/+ and MT/ShcA +/3F mammary tumors ( Figure S6 ). We show that breast cancer cells with an intact ShcA pathway are more reliant on PGC-1 to support their growth, even under nutrient replete conditions ( Figure 5B, C) . Moreover, the ability of ShcA signaling to cope with phenformin requires PGC-1 ( Figure 5B , C). These data support an essential role for PGC-1 in increasing glucose metabolism (40). Finally, PGC-1 is also required to permit Shc3F cells to withstand glucose withdrawal, further reinforcing its essential role in mitochondrial metabolism ( Figure 5B , C).
To further substantiate an essential role for PGC-1 in ShcA-driven breast cancer progression, we ectopically expressed PGC-1 in Shc3F cells or stably deleted PGC-1 from ShcA WT and Shc3F cells by Crispr/Cas9 gene editing ( Figure 5D , E). We used two independent guides directed to the second exon of PGC-1. PGC-1 null cells encode the first 57 (Crispr #1) or 37 (Crispr #2) amino acids of PGC-1 prior to introduction of a pre-mature stop codon. We show that Shc3F cells better tolerated PGC-1 loss, whereas PGC-1 was key for ShcA WT cell viability ( Figure 5D ), confirming the fact that ShcA signaling increases the PGC-1 dependency of breast cancer cells ( Figure 5B , C). This suggests that the PGC-1-null, ShcA WT clones likely significantly re-wired their metabolism. Moreover, reduced ShcA signaling permits cancer cells to adapt to PGC-1 on July 20, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472. loss under nutrient replete conditions. Hence, we focused our attention on understanding the effects of PGC-1 loss on the tumorigenic potential of Shc3F cells.
We first examined how nutrient deprivation modulated PGC-1 levels in breast cancer cells. Although endogenous Ppargc1a (PGC-1) levels are basally low in Shc3F cells, Ppargc1a is strongly induced in these cells (40 fold) upon glucose deprivation. In contrast, PGC-1 overexpressing cells modestly upregulated Ppargc1a levels (2 fold) in the absence of glucose ( Figure 5E ). Moreover, Ppargc1a mRNA levels were not appreciably induced in PGC-1 null cells, supporting the fact that PGC-1 transcriptionally controls its own promoter (41) ( Figure 5E ). We also examined how PGC-1 and ERR levels are controlled by alterations in ShcA signaling and/or PGC-1 expression. PGC-1 is a closely related family member (42) and ERR is an orphan nuclear receptor that preferentially dimerizes with PGC-1 to coordinate expression of metabolic genes (43). Ppargc1b is modestly repressed in Shc3F cells (1.4 fold), whereas Esrra expression is unaffected by the ShcA pathway in high glucose conditions ( Figure   5E ). Glucose deprivation upregulates Ppargc1b and Esrra expression in both cell lines.
However, Shc3F cells show a greater Ppargc1b and Esrra induction ( Figure 5E ). PGC-1 overexpression has little to no impact on endogenous Ppargc1b and Esrra levels, in glucose-depleted conditions ( Figure 5E ), given that PGC-1 levels are already significantly induced (Figure. 5A) . In contrast, PGC-1 loss significantly impaired the ability of breast cancer cells to upregulate Ppargc1b (2.5 fold) and Esrra (2 fold) following glucose deprivation ( Figure 5E ). Next, we tested the impact of PGC-1 overexpression or loss on the growth potential of Shc3F cells. Under control conditions, both PGC-1 overexpression and loss decreased the growth potential of Shc3F cells relative to empty vector controls, suggesting that PGC-1 levels must be tightly controlled to maintain metabolic functions ( Figure 5F ). Previous studies suggest that cells have a narrow window of tolerance for PGC-1 levels (38, 44, 45) . While PGC-1 overexpression increased the viability of breast cancer cells in response to glucose and glutamine withdrawal, PGC-1 loss further sensitized them to nutrient deprivation ( Figure 5G, H) . Similarly, PGC-1 overexpression protected breast cancer cells to phenformin while PGC-1 loss further sensitized them to this biguanide ( Figure 5I ). These data suggest that PGC-1 overexpression endows breast cancer cells with increased metabolic capacities, while PGC-1 loss may be deleterious for cancer cell growth, which requires significant metabolic investment. To test this in vivo, we injected ShcA WT , Shc3F (EV), PGC-1 overexpressing, PGC-1 Crispr #1 and PGC-1 Crispr #2 cells into the mammary fat pads of immunodeficient mice. As expected, Shc3F cells display delayed tumor onset ( Figure 6A ) and impaired tumor growth ( Figure 6B ) relative to ShcA WT cells. PGC-1 overexpression modestly increased tumor onset and growth, suggesting that PGC-1 is insufficient to restore the tumorigenic potential of breast cancers that are debilitated in ShcA signaling. This is consistent with the fact that PGC-1 overexpression did not rescue the proliferative, apoptotic and angiogenic defects of Shc3F tumors ( Figure S7 ).
We also tested whether PGC-1 is necessary for breast cancer progression.
Markedly, PGC-1 loss profoundly delayed breast tumor onset (EV: T 50 =16d; CR1: Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472.CAN-17-3696 T 50 =48d; CR2: T 50 =26d) ( Figure 6A ). As expected, Sod2 levels (a PGC-1 target gene) were significantly reduced in PGC-1 null cells upon glucose deprivation relative to empty vector controls ( Figure 6C ). In contrast, Gls1 levels were comparable between PGC-1α (CR#2) and EV control cells ( Figure 6C ), which may explain why tumor onset was less severely impaired with the PGC-1α (CR#2) cohort ( Figure 6A ). However, PGC-1 was dispensable for tumor growth ( Figure 6B ). This is consistent with the observation that PGC-1 null tumors display comparable rates of proliferation, apoptosis and angiogenesis relative to empty vector controls ( Figure S7 ). Collectively, these data suggest that PGC-1 serves an essential and non-redundant role during tumor emergence.
Moreover, significant selective pressures are exerted upon PGC-1 null tumors to reprogram their metabolism for subsequent tumor growth. Indeed, we recently showed that PGC-1α increases the global bioenergetic capacity and flexibility of breast cancer cells by increasing ATP production, both through increased glycolysis and oxidative phosphorylation (46). (Figure 6E, F) . In stark contrast, phenformin significantly reduced the number of tumor bearing glands (average 8 vs 5 tumors) in MT/ShcA +/3F animals ( Figure 6D ). Moreover, phenformin-treated MT/ShcA +/3F mice showed a significantly reduced tumor volumes (3.8 fold) compared to control animals ( Figure 6E, F) . These data suggest that the ability of biguanides to reduce breast cancer incidence critically depends on the ShcA activation status in the breast epithelium.
The ability of biguanides to impair breast tumor initiation is attenuated by
Taken together, our observations demonstrate that elevated ShcA signaling engages PGC-1α to increase the metabolic rate and bioenergetic flexibility of breast cancers. This ShcA/PGC-1α axis contributes significantly to breast tumor emergence and growth along with resistance to biguanides.
DISCUSSION
Numerous studies have implicated dysregulated receptor tyrosine kinase (RTK) signaling in metabolic re-programming. For example, ErbB2 stimulates glycolytic metabolism in cancer cells, in part, through its ability to upregulate the expression of glycolytic enzymes (20). Breast cancer cells that develop resistance to ErbB2-targeted therapies increase their rate of glycolysis and can also be sensitized to glycolytic inhibitors (5, 6) . This re-enforces the idea that metabolic reprogramming towards a on July 20, 2018. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472.CAN-17-3696 glycolytic phenotype is an essential feature of RTK-driven breast tumors. In this study, we provide the first genetic evidence that the ShcA adaptor transduces oncogenic signals that permit metabolic perturbations underlying the glucose dependency of breast cancers.
To cope with their increased metabolic rate, breast tumors that hyperactivate ShcA signaling significantly upregulate PGC-1 levels, leading to elevated mitochondrial metabolism and glucose supply (40). Thus, the ShcA/PGC-1 signaling axis is likely to create a feed forward mechanism to ensure that the proliferative and metabolic needs of aggressive breast tumors are continuously met (Figure 7 ). This is consistent with the fact that PGC-1α is essential to support a higher metabolic rate in aggressive breast cancers. We recently demonstrated that PGC-1α also promotes bioenergetic flexibility, meaning that elevated PGC-1α levels readily allow cancer cells to switch between mitochondrial and glycolytic metabolism for ATP production (46). Increased ShcA signaling decreases the dependence of breast tumors on either pathway for energy production, rendering them less sensitive to biguanides, which block mitochondrial respiration. In contrast, impaired ShcA signaling lowers PGC-1α levels, which decreases the mitochondrial capacity of breast cancer cells yet renders them more dependent on mitochondrial metabolism, which sensitizes them to biguanides (Figure 7) . metformin was administered to non-diabetic breast cancer patients in the neo-adjuvant setting showed decreased cell proliferation, which was associated with reduced insulin receptor expression and signaling in metformin-treated tumors (52). This study provided the first experimental evidence that metformin may exert anti-neoplastic activities in breast cancers. Given these observations, activation of the ShcA signaling pathway, may help determine breast cancer patients that would achieve maximal benefit from biguanides.
Globally, our work highlights the importance of metabolism in fuelling RTK/ShcA signalling during all stages of the tumorigenic program. We show that the ShcA pathway increases PGC-1α driven metabolic re-programming to augment the metabolic rate of mammary tumors and render them resistant to agents that target mitochondrial metabolism. This suggests that the ShcA/PGC-1α axis may define sensitivity to Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
FIGURE LEGENDS
Shc3F cells cultured in high (25 mM) or no (0 mM) glucose for 3 days. The data is shown as fold change in metabolite levels following glucose withdrawal compared to 25 mM glucose conditions ± SEM and is representative of three independent experiments.
Metabolite levels for the high glucose condition (average ± SD) is shown. The raw data can be found in Figure S2A. (B Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 21, 2018; DOI: 10.1158/0008-5472. By decreasing signaling downstream of ShcA, glucose metabolism is debilitated in breast cancer cells, which increases their dependency on mitochondrial metabolism for ATP production, exposing a therapeutic vulnerability to increased biguanide sensitivity. 
